SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

VivoSim Labs Partners With Chemveda on AI-Designed Drug Screening

The companies will combine compound design and synthesis with screening in VivoSim’s human liver and intestine tissue models. The joint offering is expected to launch in Q4 2026; financial terms were not disclosed.

VIVS
SquawkNews Desk

Related stories

TransAlta shares rise 7.7% as net earnings turn positive M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC IPG Photonics Reports Third-Quarter 2026 Revenue of $287.5 Million Revenue rose 15% year over year and exceeded FactSet estimates of $283.3 million. Adjusted EPS was $0.61 versus consensus of $0.49. IPG guided to fourth-quarter revenue of $265 mil M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC DigitalOcean Reports Q3 Revenue of $321 Million, Raises 2026 Outlook Third-quarter revenue rose 40% year over year to $321 million; adjusted EPS was $0.45 versus FactSet consensus of $0.32. The company guided fourth-quarter revenue to $348 million–$ M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC Ball shares fall about 5% as company swings to Q3 loss M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC Aehr Test Systems shares jump 14.6% after Q1 results beat M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC S&P 500 and Nasdaq Open Higher as Oil Prices Extend Declines U.S. stocks opened higher as oil prices extended their declines, with midterm elections on the agenda. M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC